Abstract:The discovery that subanesthetic doses of (R, S)-ketamine (ketamine) and (S)-ketamine (esketamine) rapidly induce antidepressant effects and promote sustained actions following drug clearance in depressed patients who are treatment-resistant to other therapies has resulted in a paradigm shift in the conceptualization of how rapidly and effectively depression can be treated. Consequently, the mechanism(s) that next generation antidepressants may engage to improve pathophysiology and resultant symptomology are being reconceptualized. Impaired excitatory glutamatergic synapses in mood-regulating circuits are likely a substantial contributor to the pathophysiology of depression. Metaplasticity is the process of regulating future capacity for plasticity by priming neurons with a stimulation that alters later neuronal plasticity responses. Accordingly, the development of treatment modalities that specifically modulate the duration, direction, or magnitude of glutamatergic synaptic plasticity events such as long-term potentiation (LTP), defined here as metaplastogens, may be an effective approach to reverse the pathophysiology underlying depression and improve depression symptoms. We review evidence that the initiating mechanisms of pharmacologically diverse rapid-acting antidepressants (i.e., ketamine mimetics) converge on consistent downstream molecular mediators that facilitate the expression/maintenance of increased synaptic strength and resultant persisting antidepressant effects. Specifically, while the initiating mechanisms of these therapies may differ (e.g., cell type-specificity, N-methyl-D-aspartate receptor (NMDAR) subtype-selective inhibition vs activation, metabotropic glutamate receptor 2/3 antagonism, AMPA receptor potentiation, 5-HT receptor-activating psychedelics, etc.), the sustained therapeutic mechanisms of putative rapid-acting antidepressants will be mediated, in part, by metaplastic effects that converge on consistent molecular mediators to enhance excitatory neurotransmission and altered capacity for synaptic plasticity. We conclude that the convergence of these therapeutic mechanisms provides the opportunity for metaplasticity processes to be harnessed as a druggable plasticity mechanism by next-generation therapeutics. Further, targeting metaplastic mechanisms presents therapeutic advantages including decreased dosing frequency and associated diminished adverse responses by eliminating the requirement for the drug to be continuously present.

Potentiation of AMPA receptors for rapid therapeutic gain in psychiatry has reached a new level of excitement

Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide

Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics

Ketamine and the Future of Rapid-Acting Antidepressants

Clinical pharmacological innovation in the treatment of depression

Fragile promise of psychedelics in psychiatry

Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression

Synaptic basis of rapid antidepressant action

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

Targeting metaplasticity mechanisms to promote sustained antidepressant actions

Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

Rapid-acting antidepressants targeting modulation of the glutamatergic system: clinical and preclinical evidence and mechanisms

Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections

Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms

Psychoactive substances for the treatment of neuropsychiatric disorders

Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy

A Bright Future of Researching AMPA Receptor Agonists for Depression Treatment

The Promise of a Novel Treatment for Psychiatric and Neurological Disorders

Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments

The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug